➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Colorcon
Harvard Business School
Baxter
McKinsey

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Litigation Details for ALLERGAN SALES, LLC v. SANDOZ, INC. (D.N.J. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

ALLERGAN SALES, LLC v. SANDOZ, INC. (D.N.J. 2017)

Docket   Start Trial Date Filed 2017-10-30
Court District Court, D. New Jersey Date Terminated
Cause 35:271 Patent Infringement Assigned To Claire Claudia Cecchi
Jury Demand Both Referred To Mark Falk
Parties ALCON LABORATORIES, INC.
Patents 7,030,149; 7,320,976; 7,323,463; 7,642,258; 8,133,890; 8,354,409; 8,748,425; 9,474,751; 9,770,453; 9,907,801; 9,907,802
Attorneys AHMED MUHAMMED TAN RIAZ
Firms Eric I. Abraham
Link to Docket External link to docket
Small Molecule Drugs cited in ALLERGAN SALES, LLC v. SANDOZ, INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for ALLERGAN SALES, LLC v. SANDOZ, INC. (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-10-30 1 formulation of Combigan®. The listed patents are U.S. Patent Nos. 7,030,149, 7,320,976, 7,642,258, 8,133,890…infringed U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258, and that those patents were not …latest of the expiration dates of U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258. …that the claims of the ’149 patent, ’258 patent, ’976 patent, and ’425 patent are invalid and/or will not… infringement of United States Patent No. 9,770,453 (the “’453 patent”) under 35 U.S.C. § 271(e)(2) and External link to document
2018-05-22 112 the first patent from which issued in 2006, U.S. Patent No. 7,030,149 (the “’149 patent”). (Id. ¶¶…the “’801 patent”), and 9,907,802 (the “’802 patent). These patents all stem from a patent application… ’149 patent, the ’425 patent, and a third patent from the first litigation, the ’976 patent. 6 (Id…other patents, U.S. Patent Nos. 8,133,890 (the “’890 patent”) and 8,354,409 (the “’409 patent”) that…Allergan Patent Family beginning with the first patent of this family, the ’149 patent. The inequitable External link to document
2018-07-26 166 Redacted Document 149 patent U.S. Patent No. 7,030,149 (Ex. 5) °976 patent U.S. Patent No. 7,320,976 (Ex. 6) °258 patent U.S…methods of treatment. (32); see U.S. Pat. Nos. 7,030,149, 7,323,463, 8,133,890, 8,354,409, 8,748,425, 9,770,453…Apr. 13, 2012) °453 patent U.S. Patent No. 9,770,453 (Ex. 1) °801 patent U.S. Patent No. 9,907,801 (Ex.…Ex. 2) °802 patent U.S. Patent No. 9,907,802 (Ex. 3) °463 patent USS. Patent No. 7,323,463 (Ex. 4) °149… U.S. Patent No. 7,642,258 (Ex. 7) °409 patent U.S. Patent No. 8,354,409 (Ex. 8) °890 patent U.S. Patent External link to document
2018-08-02 173 Opinion District of Texas, asserting related patents U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,…asserts three patents: U.S. Patent Nos. 9,770,453 (“the ’453 patent”); 9,907,801 (“the ’801 patent”); and 9,907,802…complaint asserts three patents: the ’453 patent, the ’801 patent, and the ’802 patent, Am. Compl. 11 1, ECF…PUBLICATION B. Patent prosecution Defendants claim that during the l6-year prosecution of` this patent family…claim that during prosecution of the ’802 patent (one of the patents in suit), Allergan disclosed some of External link to document
2017-12-19 18 formulation of Combigan®. The listed patents are U.S. Patent Nos. 7,030,149, 7,320,976, 7,642,258, 8,133,890…infringed U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258, and that those patents were not …of U.S. Pat. Nos. 7,030,149 (“the ’149 patent”) and 7,320,976 (“the ’976 patent”) on December 30, …latest of the expiration dates of U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258. … No. 91-087 infringed claim 4 of U.S. Patent No. 7,030,149, claim 1 of U.S. Pat. No. 7,320,976, claims External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Colorcon
McKinsey
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.